Philip Lienau

The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models

Antje M. Wengner, Gerhard Siemeister, Ulrich Lücking et al. · Molecular Cancer Therapeutics · 2019 · 200 citations

Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer

Ulrich Lücking, Arne Scholz, Philip Lienau et al. · ChemMedChem · 2017 · 176 citations · Full text

The Lab Oddity Prevails: Discovery of Pan‐CDK Inhibitor (<i>R</i>)‐<i>S</i>‐Cyclopropyl‐<i>S</i>‐(4‐{[4‐{[(1<i>R</i>,2<i>R</i>)‐2‐hydroxy‐1‐methylpropyl]oxy}‐5‐(trifluoromethyl)pyrimidin‐2‐yl]amino}phenyl)sulfoximide (BAY 1000394) for the Treatment of Cancer

Ulrich Lücking, Rolf Jautelat, Martin Krüger et al. · ChemMedChem · 2013 · 173 citations

Aminopyrimidine Zk 304709, Lab Oddity Prevails, Lead Identification +21

Mechanism-Based Inhibition: Deriving KI and kinact Directly from Time-Dependent IC50 Values

Ben‐Fillippo Krippendorff, Roland Neuhaus, Philip Lienau et al. · SLAS DISCOVERY · 2009 · 154 citations · Full text

BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application

Gerhard Siemeister, Ulrich Lücking, Antje M. Wengner et al. · Molecular Cancer Therapeutics · 2012 · 154 citations · Full text

Oral Application, Chemoprevention Strategy, Retinoblastoma Protein +19